A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Phase 1
96
about 12 months
18–65
1 site in IL
What this study is about
This trial is testing a treatment called ABBV-295, given as subcutaneous injections, in adults with obesity. The goal is to see what side effects occur and how the body processes this medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ABBV-295
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Area under the plasma concentration-time curve (AUC) of ABBV-295, Dose Normalized AUC of ABBV-295, Dose Normalized Cmax of ABBV-295, Incidence of Anti-Drug Antibodies (ADAs), Maximum Observed Plasma Concentration (Cmax) of ABBV-295, Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements, Number of Participants with Adverse Events (AEs), Number of Participants with Change from Baseline in Electrocardiogram (ECG)
Endocrinology